Tianhe Co., Ltd.: the directors and senior executives of the company plan to hold an additional 2.5-4.95 million yuan of shares

Survival Rules for Turbulent Times: A Compilation of the 20 Most Unmissable Core Insights from the 2026 Tsinghua PBCSF Forum

A dialogue between Zhu Min, former Deputy Governor of the People's Bank of China and former Vice Managing Director of the International Monetary Fund; Michael Spence, 2001 Nobel Prize winner in Economics and Philip H. Knight Professor Emeritus of Management at Stanford Graduate School of Business; and Masaaki Shirakawa, former Governor of the Bank of Japan, at the 2026 Tsinghua PBCSF Global Finance Forum.

Unpacking China | Key Chinese Firms to Watch This Week （26/07/2026-01/08/2026）

Amid fast-paced changes that fill the business community with excitement, angst and trepidation, EqualOcean will publish a series of roundup articles to document the major events related to Chinese companies going global every week.

Precision Reducer Manufacturer Talls Intelligent Technology Secures CNY 140 Million in Financing

Talls Intelligent Technology（陶世智能）Raises CNY 140 Million, Secures Order for 100,000 Dexterous Hands

SEEV Raises Nearly CNY 200 Million in Two Funding Rounds, Targeting Mass-Production Window for Full-Color AR Waveguides

EO reported on August 5 that AR diffractive waveguide manufacturer SEEV（广纳四维）had completed two consecutive funding rounds, raising nearly CNY 200 million in total.

Alphamab Licenses Cancer Drug to Pathos AI in Deal Worth More Than US$2.2 Billion

Alphamab Oncology (康宁杰瑞生物制药) has licensed the overseas rights to its experimental cancer drug JSKN016 to US-based Pathos AI in a deal potentially worth more than US$2.2 billion, marking another major overseas licensing agreement for China’s rapidly expanding innovative-drug sector.